Esco Aster provides specialized cell culture media development, optimization, benchmarking, and cost-reduction services across cell therapy, gene therapy, extracellular vesicles, and advanced biomanufacturing applications.
Our capabilities span from media formulation and ingredient qualification to process-specific optimization and commercial-scale media supply. We leverage qualified Asia-Pacific suppliers and alternative raw materials—from amino acids and growth factors to functional additives—to identify cost-effective alternatives without compromising critical performance attributes.
With a track record spanning cell-based nutrition and food manufacturing, stem cell bioprocessing, viral vector production, and extracellular vesicle/exosome manufacturing, Esco Aster is positioned to work with startups and established organizations at different stages of development.
Media development can be provided as a standalone service or integrated with our cell line creation, cell line development, process development, and biomanufacturing services, enabling media and cell/process parameters to be optimized together rather than independently.
Esco Aster specializes in developing and optimizing media for both conventional and advanced 3D cell culture platforms, including our fixed packed bed Tide Motion bioreactor (adherent cells and derivatives) or TideWave™ bioreactor (immune cell and derivatives), suspension bioreactors in orbital format (10L) or stirred tank 500L (with or without microcarrier culture).
Our capabilities include:
Esco Aster can reformulate existing commercial or proprietary media to achieve a more competitive cost structure while maintaining the required biological performance.
Examples include:
Beyond basal media development, Esco Aster develops functional media additives and process-specific enhancers designed to improve cell performance, productivity, recovery, and product quality.
For high-density 3D viral production, excessive cellular stress and reactive oxygen species (ROS) generation can negatively affect cell health and viral productivity. Esco Aster develops virus-specific enhancement strategies designed to modulate cellular stress and improve viral productivity, where appropriate.
Potential applications include:
Esco Aster develops media and supplementation strategies tailored to the specific producer cell and desired extracellular vesicle profile, with objectives including:
Our immune-cell media and enhancer capabilities include:
Esco Aster has developed the following cell cuture media products for specific production cell lines and applications, including:
Esco Aster can support the transition from laboratory-scale formulation to manufacturing-scale media supply, reducing the gap between media development and commercial implementation.
Our capabilities include:
Formulation → Benchmarking → Optimization → Raw Material Qualification → Scale-Up → Blending → Filling
For qualified formulations, Esco Aster can provide dry-powder blended media (made by qualified partners) as well as liquid media manufacturing and contract filling through our food-grade and clinical/ gmp grade manufacturing capabilities, with MOQ options from approximately 500 L for bottled media, subject to formulation and product requirements.
Media development can be integrated with complementary analytical services to establish the relationship between media composition, cellular performance, and product output.
Related services include:
Esco Aster can help as required to perform clinical study, trials, clinical development, register and file if needed to Usa DMF. Typical examples will be for IVF Media, Injectable grade cryopreservation.
Esco Aster can also provide cold chain storage and work with 3rd Party Logistics for point-to-point delivery within South Asia/Asean/Anz.
Esco Aster's key differentiation is the ability to develop media in the context of the entire bioprocess rather than as an isolated formulation exercise.
By combining media development with cell line development, 3D Tide Motion bioreactors, process development, analytical characterization, clinical development and cGMP manufacturing, we can optimize the interaction between cell, media, bioreactor, and process from the outset—helping clients achieve higher productivity, lower media costs, and a more scalable manufacturing process.